HUP0402486A2 - Nitrogéntartalmú heterociklusos vegyületek, mint peroxiszóma proliferátorral aktivált receptor agonisták, az ezeket tartalmazó gyógyászati készítmények és alkalmazásuk - Google Patents
Nitrogéntartalmú heterociklusos vegyületek, mint peroxiszóma proliferátorral aktivált receptor agonisták, az ezeket tartalmazó gyógyászati készítmények és alkalmazásukInfo
- Publication number
- HUP0402486A2 HUP0402486A2 HU0402486A HUP0402486A HUP0402486A2 HU P0402486 A2 HUP0402486 A2 HU P0402486A2 HU 0402486 A HU0402486 A HU 0402486A HU P0402486 A HUP0402486 A HU P0402486A HU P0402486 A2 HUP0402486 A2 HU P0402486A2
- Authority
- HU
- Hungary
- Prior art keywords
- alkyl
- group
- optionally substituted
- aryl
- heteroaryl
- Prior art date
Links
- -1 Nitrogen containing heterocyclic compounds Chemical class 0.000 title abstract 2
- 239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 230000008878 coupling Effects 0.000 abstract 2
- 238000010168 coupling process Methods 0.000 abstract 2
- 238000005859 coupling reaction Methods 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 abstract 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 125000004422 alkyl sulphonamide group Chemical group 0.000 abstract 1
- 125000005418 aryl aryl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000006520 cycloalkyl aryl alkyl group Chemical group 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical class C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 150000003536 tetrazoles Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
A találmány tárgyát képezik az (I) általános képletű peroxiszómaproliferátorral aktivált receptorok agonistái, az ezeket tartalmazógyógyászati készítmények, és alkalmazásuk például diabetes mellitus,szív- és érrendszeri betegségek, elhízottság, gyulladásos betegségekés hasonlók kezelésére szolgáló gyógyszerkészítmények előállítására.Az (I) általános képletben a szubsztituensek jelentése igen sokfélelehet, így például (a) R1 jelentése hidrogénatom, alkil-, aril-alkil-,heteroaril-alkil-, cikloalkil-aril-alkilcsoport, amely csoportok mindadott esetben szubsztituálva lehetnek; (b) R2 jelentése példáulalkil-, alkenil-, aril-alkil-, heteroaril-alkil-, alkil-szulfon-amid-;vagy 3-6 szénatomos cikloalkilcsoport, amely csoportok mind adottesetben szubsztituálva lehetnek; (c) W jelentése O vagy S; (d) Xjelentése adott esetben szubsztituált 1-5 szénatomos alkilén kapcsolócsoport, ahol a kapcsoló csoportban lévő egyik szénatom helyett adottesetben O, NH vagy S állhat, továbbá adott esetben két szénatom közöttkettős kötés van jelen; (e) Y jelentése C, O, S, NH és vegyértékkötésközül választott; és (f) E jelentése C(R3)(R4)A, A, és adott esetbenszubsztituált (CH2)nCOOR19 közül választott: és ahol (i) n értéke 0,1, 2 vagy 3,[ii] A jelentése például karboxil-, karboxamid-, adottesetben szubsztituált tetrazol vagy izoxazol; (iii) R3 jelentésealkil- vagy alkoxicsoport és R4 jelentése például adott esetbenszubsztituált alkil-, alkoxi-, cikloalkil-, aril-alkil- vagyfenilcsoport; R8 jelentése például alkil-, alkenil- vagy halogénatom;R9 jelentése például alkilcsoport, halogénatom, szubsztituált aril-,heteroarilcsoport és hasonlók; R21 jelentése például hidrogén- vagy =Ovagy adott esetben szubsztituált alkil-, aril- vagy heteroarilcsoport;R22 jelentése például adott esetben szubsztituált alkil-; aril- vagyheteroarilcsoport, továbbá a - - - - jelentése adott esetben jelenlévőkettős csoport. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33445301P | 2001-11-30 | 2001-11-30 | |
| PCT/US2002/036128 WO2003048130A2 (en) | 2001-11-30 | 2002-11-26 | Peroxisome proliferator activated receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0402486A2 true HUP0402486A2 (hu) | 2005-03-29 |
| HUP0402486A3 HUP0402486A3 (en) | 2007-05-02 |
Family
ID=23307275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0402486A HUP0402486A3 (en) | 2001-11-30 | 2002-11-26 | Nitrogen containing heterocyclic compounds as peroxisome proliferator activated receptor agonists, their use and pharmaceutical compositions cointaining them |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7544812B2 (hu) |
| EP (1) | EP1453811A2 (hu) |
| JP (1) | JP2005517643A (hu) |
| KR (1) | KR20050044606A (hu) |
| CN (1) | CN1582279A (hu) |
| AU (1) | AU2002356927A1 (hu) |
| BR (1) | BR0214437A (hu) |
| CA (1) | CA2468846A1 (hu) |
| CO (1) | CO5640129A2 (hu) |
| EA (1) | EA007163B1 (hu) |
| HR (1) | HRP20040469A2 (hu) |
| HU (1) | HUP0402486A3 (hu) |
| IL (1) | IL161578A0 (hu) |
| MX (1) | MXPA04005123A (hu) |
| NO (1) | NO20042737L (hu) |
| NZ (1) | NZ532909A (hu) |
| PL (1) | PL370515A1 (hu) |
| WO (1) | WO2003048130A2 (hu) |
| ZA (1) | ZA200404173B (hu) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0311834A (pt) | 2002-06-19 | 2005-04-12 | Lilly Co Eli | Composto, composição farmacêutica, métodos para mudular um receptor ativado por proliferador de peroxisoma, para tratar e prevenir diabetes mellitus em um mamìfero e para tratar sìndrome x em um mamìfero, e, uso de um composto ou seu sal farmaceuticamente aceitável |
| US7816385B2 (en) * | 2002-12-20 | 2010-10-19 | High Point Pharmaceuticals, Llc | Dimeric dicarboxylic acid derivatives, their preparation and use |
| DE10351859A1 (de) * | 2003-11-06 | 2005-06-09 | Beiersdorf Ag | Emulsionen mit zwei Verdickungsmitteln |
| EP2305352A1 (en) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders |
| US7456164B2 (en) | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
| BRPI0516217A (pt) * | 2004-09-28 | 2008-08-26 | Allergan Inc | compostos de 4-benzil-1,3-diidro-imidazol-2-tionas não-substituìdos e substituìdos que atuam como agonistas especìficos ou seletivos alfa2-adrenérgicos e métodos de utilização dos mesmos |
| AU2007260985A1 (en) | 2006-06-20 | 2007-12-27 | Wyeth | Imidazolidinone Kv1.5 potassium channel inhibitors |
| FR2903984B1 (fr) * | 2006-07-24 | 2008-10-03 | Genfit Sa | Derives d'imidazolones substitues, preparation et utilisations |
| US20100183696A1 (en) * | 2007-01-30 | 2010-07-22 | Allergan, Inc | Treating Ocular Diseases Using Peroxisome Proliferator-Activated Receptor Delta Antagonists |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| DK2170930T3 (da) | 2007-06-04 | 2012-11-05 | Synergy Pharmaceuticals Inc | Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme |
| CA2726917C (en) | 2008-06-04 | 2018-06-26 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| CA2730603C (en) | 2008-07-16 | 2019-09-24 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| CN101875636B (zh) * | 2010-05-18 | 2012-01-04 | 浙江大学 | 咪唑啉-2,4-二酮类衍生物及制备方法和用途 |
| WO2012027331A1 (en) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| WO2014151200A2 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| HRP20240805T1 (hr) | 2013-06-05 | 2024-09-27 | Bausch Health Ireland Limited | Ultra-pročišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i uporabe |
| CN114835655A (zh) * | 2022-04-14 | 2022-08-02 | 河南师范大学 | 一种合成光学活性三氟甲基丙烯酸酯类化合物的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3452041A (en) * | 1965-05-19 | 1969-06-24 | American Home Prod | Hydantoin compounds and methods of preparation |
| NZ184281A (en) | 1976-06-03 | 1980-04-28 | Wellcome Found | Hydantoin derivatives and pharmaceutical compositions |
| GB1601310A (en) * | 1978-05-23 | 1981-10-28 | Lilly Industries Ltd | Aryl hydantoins |
| JPS59159163A (ja) * | 1983-03-01 | 1984-09-08 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−感光材料 |
| GB9604242D0 (en) * | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
| DE69811867T2 (de) | 1997-03-03 | 2003-11-20 | Boehringer Ingelheim Pharmaceuticals, Inc. | Kleine moleküle anwendbar in der behandlung von entzündgskrankheiten |
| ATE252091T1 (de) | 1999-08-27 | 2003-11-15 | Lilly Co Eli | Biaryl-oxa(thia)zolderivate und ihre verwendung als ppars modulatoren |
-
2002
- 2002-11-26 CA CA002468846A patent/CA2468846A1/en not_active Abandoned
- 2002-11-26 EA EA200400748A patent/EA007163B1/ru not_active IP Right Cessation
- 2002-11-26 AU AU2002356927A patent/AU2002356927A1/en not_active Abandoned
- 2002-11-26 PL PL02370515A patent/PL370515A1/xx not_active Application Discontinuation
- 2002-11-26 WO PCT/US2002/036128 patent/WO2003048130A2/en active Application Filing
- 2002-11-26 HU HU0402486A patent/HUP0402486A3/hu unknown
- 2002-11-26 JP JP2003549322A patent/JP2005517643A/ja active Pending
- 2002-11-26 NZ NZ532909A patent/NZ532909A/en unknown
- 2002-11-26 MX MXPA04005123A patent/MXPA04005123A/es unknown
- 2002-11-26 KR KR1020047008021A patent/KR20050044606A/ko not_active Application Discontinuation
- 2002-11-26 US US10/496,770 patent/US7544812B2/en not_active Expired - Fee Related
- 2002-11-26 IL IL16157802A patent/IL161578A0/xx unknown
- 2002-11-26 EP EP02804416A patent/EP1453811A2/en not_active Withdrawn
- 2002-11-26 CN CNA028238001A patent/CN1582279A/zh active Pending
- 2002-11-26 BR BR0214437-9A patent/BR0214437A/pt not_active IP Right Cessation
-
2004
- 2004-05-27 ZA ZA200404173A patent/ZA200404173B/en unknown
- 2004-05-27 CO CO04049275A patent/CO5640129A2/es not_active Application Discontinuation
- 2004-05-27 HR HR20040469A patent/HRP20040469A2/hr not_active Application Discontinuation
- 2004-06-29 NO NO20042737A patent/NO20042737L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002356927A1 (en) | 2003-06-17 |
| US7544812B2 (en) | 2009-06-09 |
| WO2003048130A2 (en) | 2003-06-12 |
| WO2003048130A3 (en) | 2003-11-20 |
| CN1582279A (zh) | 2005-02-16 |
| HRP20040469A2 (en) | 2004-10-31 |
| EA200400748A1 (ru) | 2004-12-30 |
| CA2468846A1 (en) | 2003-06-12 |
| EP1453811A2 (en) | 2004-09-08 |
| KR20050044606A (ko) | 2005-05-12 |
| NO20042737L (no) | 2004-08-17 |
| US20050020652A1 (en) | 2005-01-27 |
| HUP0402486A3 (en) | 2007-05-02 |
| MXPA04005123A (es) | 2005-02-17 |
| PL370515A1 (en) | 2005-05-30 |
| JP2005517643A (ja) | 2005-06-16 |
| EA007163B1 (ru) | 2006-08-25 |
| BR0214437A (pt) | 2004-10-13 |
| ZA200404173B (en) | 2005-08-23 |
| IL161578A0 (en) | 2004-09-27 |
| NZ532909A (en) | 2006-08-31 |
| CO5640129A2 (es) | 2006-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0402486A2 (hu) | Nitrogéntartalmú heterociklusos vegyületek, mint peroxiszóma proliferátorral aktivált receptor agonisták, az ezeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
| HUP0402507A2 (hu) | N(fenilszulfonil)glicin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyászati készítmények | |
| MY140528A (en) | Spiroketal derivatives and their use as therapeutic agents for diabetes | |
| HUP0203532A2 (hu) | HPPAR-alfa aktivátor szubsztituált oxazol- és tiazolszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HUP0402310A2 (hu) | 1,6-Naftiridin-származékok mint antidiabetikumok és ezeket tartalmazó gyógyszerkészítmények | |
| HRP20070430T3 (en) | (3-oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compounds as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity | |
| HUP0301655A2 (hu) | Peroxisom proliferátor aktivált receptor alfa agonista triazolszármazékok és ezeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
| NO20061406L (no) | Organiske forbindelser | |
| HUP0302367A2 (hu) | HIV Integráz inhibitorokként hasznos aza- és poliazanaftalenil-karboxamidok, ezeket tartalmazó gyógyszerkészítmények | |
| HUP0400268A2 (hu) | Peroxiszóma proliferátorral aktivált receptorokat (PPAR) módosító hatóanyagok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0401649A2 (hu) | Benzoxazin-, benzotiazinszármazékok és gyógyszerkészítményeik | |
| DK1445258T3 (da) | Aktivator for peroxisomproliferator-aktiveret receptor delta | |
| HUP0401982A2 (hu) | Indolizinszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények | |
| TNSN07361A1 (en) | 3,4-substituted pyrrolidine derivatives for the treatment of hypertension | |
| AU4306796A (en) | Novel 3,5-dioxo-(2h,4h)-1,2,4-triazine derivatives, their preparation and use as drugs | |
| NZ532494A (en) | Dibenzylamine compound and medicinal use thereof | |
| PE20040155A1 (es) | Derivados aminoinazoles, procedimiento de preparacion e intermedios de este procedimiento a titulo de medicamentos y composiciones farmaceuticas que los contienen | |
| CA2457054A1 (en) | Activator of peroxisome proliferator-activated receptor .delta. | |
| TW200510441A (en) | Novel compounds | |
| HUP0303724A2 (hu) | Kemokin receptor inhibitor hatású bipiperidinszármazékok és ezeket tartalmazó gyógyászati készítmények, valamint eljárás a vegyületek előállítására | |
| HUP0303241A2 (hu) | Pirazolil-pirimidin-származékok, előállításuk, alkalmazásuk és az előállításukhoz használt köztitermékek | |
| ATE482933T1 (de) | Sulfopyrrolderivate | |
| HUP9904682A2 (hu) | Fenil-oxazol- és -tiazol-származékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények | |
| SE0300092D0 (sv) | Novel compounds | |
| HUP0201475A2 (hu) | Heteroarilamidin-, metilamidin- és guanidinszármazékok, előállításuk és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |